Covid-19 has had a great impact on global clinical trials, and the RELEASE study is no exception. Screening of potential patients and enrolment has slowed down, resulting in study progress falling behind schedule. PCIB still aims for an interim read out in mid-2022, but the measures to speed up study progress will increase costs. This might in turn result in fund raising earlier than expected, although with the current burn rate cash will last well into 2022.
08 May 2020
Study progression behind schedule
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Study progression behind schedule
Covid-19 has had a great impact on global clinical trials, and the RELEASE study is no exception. Screening of potential patients and enrolment has slowed down, resulting in study progress falling behind schedule. PCIB still aims for an interim read out in mid-2022, but the measures to speed up study progress will increase costs. This might in turn result in fund raising earlier than expected, although with the current burn rate cash will last well into 2022.